Emmet B. Keeffe, MD

Clinical Focus

• Hepatology (Liver)
• Chronic Hepatitis B
• Chronic Hepatitis C
• Liver Transplantation
• Gastroenterology

Administrative Appointments

• Board of Directors, American Liver Foundation, Northern California Chapter (2008 - present)
• Board of Directors, Foundation for Digestive Health and Nutrition (2004 - present)
• Chief of Hepatology, Stanford University School of Medicine (2000 - 2007)
• Co-Director, Liver Transplant Program, Stanford University Medical Center (2000 - 2007)
• Chief of Clinical Gastroenterology, Stanford University School of Medicine (1995 - 2000)
View All 8administrative appointments of Emmet Keeffe

Honors and Awards

• Honorary Fellow, Royal College of Physicians of Ireland (2006)
• Fellow, American Gastroenterological Association (2006)
• Fellow, American Society for Gastrointestinal Endoscopy (2006)
• Master, American College of Physicians (2006)
• Biographee, Who's Who in the World (2006)

Professional Education

• Fellowship: UCSF Medical Center, CA (1979)
• Board Certification: Gastroenterology, American Board of Internal Medicine (1975)
• Fellowship: Oregon Health Sciences Univ, OR (1974)
• Residency: Oregon Health Sciences Univ, OR (1973)
• Board Certification: Internal Medicine, American Board of Internal Medicine (1972)

Graduate & Fellowship Program Affiliations

• Medicine

Research Interests

My primary current clinical research interests are focused on treatment of chronic hepatitis C with nitazoxanide as well as treatment of chronic hepatitis B, application of hepatitis vaccination especially in patients with chronic liver disease, and selection and outcomes of liver transplantation. In the past, I and my colleagues have studied the role of standard interferon, interferon alfacon-1, and peginterferon alone or with ribavirin for the treatment of chronic hepatitis C. We have also documented the role of liver transplantation for fulminant hepatic failure associated with mushroom poisoning, reviewed the institutional results of new liver transplant programs, reported a variant of recurrent hepatitis B after liver transplantation called fibrosing cholestatic hepatitis, documented that the results of liver transplantation in Asian patients with chronic hepatitis B are the same as the transplant outcomes of non-Asians, assessed the quality of life following liver transplantation using a comprehensive profile of psychologic testing, reviewed selection criteria and outcomes of liver transplantation for controversial indications, defined criteria for liver transplantation and associated comorbidities in patients with alcoholic liver disease, proposed minimal listing criteria for liver transplantation, and wrote several textbook chapters on selection of patients for liver transplantation.

I have been a principle investigator in multiple clinical trials using various interferons, combined interferon or peginterferon plus ribavirin, and nitazoxanide for the treatment of chronic hepatitis C, antiviral trials using lamivudine and famciclovir for the treatment of chronic hepatitis B, optimal management of hepatitis B patients after liver transplantation, and trials of hepatitis B and hepatitis A vaccines. I reported that hepatitis A and B is more severe in patients with chronic liver disease, and demonstrated in an international trial the safety and efficacy...

Publications

• Diagnosis and treatment of chronic hepatitis B: 2009 update. Morgan M, Keeffe EB "Minerva Gastroenterol Dietol" 2009 ; 1 (55) : 5-22
• Is oral L-acyl-carnitine an effective therapy for hepatic encephalopathy? Review of the literature. Shores NJ, Keeffe EB "Dig Dis Sci" 2008 ; 9 (53) : 2330-3
• Chronic hepatitis B: preventing, detecting, and managing viral resistance. Keeffe EB, Dieterich DT, Pawlotsky JM, Benhamou Y "Clin Gastroenterol Hepatol" 2008 ; 3 (6) : 268-74
• Clinical trial: randomized, double-blind, placebo-controlled study of nitazoxanide monotherapy for the treatment of patients with chronic hepatitis C genotype 4. Rossignol JF, Kabil SM, El-Gohary Y, Elfert A, Keeffe EB "Aliment Pharmacol Ther" 2008 ; 5 (28) : 574-80
• Thiazolides: a new class of drugs for the treatment of chronic hepatitis B and C. Rossignol JF, Keeffe EB "Future Microbiol" 2008 : (3) : 539-45